Pharmaceutical Executive: What trends did you see at this year's JP Morgan Healthcare Conference? Clay Siegall: I’ve been ...

In todays pharmaceutical executive daily, Mirum Pharmaceuticals strengthens its rare disease portfolio through a $268 million ...

Biotech data visualization is often static and fragmented, limiting the ability to see integrated patient journeys and ...

According to a report from CNN, more states and pediatricians are now choosing the AAP’s guidance over a revised federal ...

Mirum Pharmaceuticals’ acquisition of Bluejay Therapeutics adds brelovitug to its pipeline, positioning the company for a potential first approved treatment for chronic hepatitis delta virus while ...

Janux Therapeutics has partnered with Bristol Myers Squibb in a global licensing and collaboration deal to advance a ...

In today's healthcare environment, securing regulatory approval is only the beginning. The real challenge lies in ensuring ...

The United States’ official exit from the World Health Organization (WHO) is set to be finalized today, Thursday January 22, ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

GSK entered into a definitive agreement to acquire RAPT Therapeutics, including RAPT’s long-acting anti-immunoglobulin E (IgE ...

Global pharmaceutical production surged in 2025 due to tariff-driven front-loading but is expected to slow as trade ...

AI can accelerate drug discovery, clinical development, and patient access, but regulatory hurdles remain. Anders Romare, ...